Scinai Immunotherapeutics Ltd
scinai.comWhat Do They Do?
Develops antibody-based drug candidates for inflammatory and immune conditions and provides development and manufacturing services to biotechnology companies.
20-F for FY2025, filed Apr 1, 2026We are a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of innovative…View ↗
NanoAbs Platform – We are developing a pipeline of novel therapeutics based on NanoAbs (VHH antibody fragments), which possess unique…View ↗
Our CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients…View ↗
How Do They Make Money?
Biotechnology customers pay for process and analytical development, quality testing, and clinical-material manufacturing. Scinai earns money as some project work progresses and at a delivery point for other services.
20-F for FY2025, filed Apr 1, 2026Under its CDMO agreements, the Company provides a combination of services, which may include:View ↗
Manufacturing services: The Company utilizes its facilities and equipment to manufacture pharmaceutical products in accordance with…View ↗
Quality assurance and control: The Company applies its quality management system to ensure compliance with applicable regulatory…View ↗
Process and analytical method development: The Company assists customers in developing or optimizing manufacturing processes and analytical…View ↗
Year ended December 31, 2025 2024 2023 Revenues from CDMO recognized Over time $ 406 $ 496 $ - Revenues from CDMO recognized Point in time…View ↗
$1.3M
-
20-F for FY2025, filed Apr 1, 2026
$1.3M ↗
Who Are Their Customers?
Small and emerging biotechnology companies use Scinai for development and clinical-stage manufacturing services; Scinai reaches prospective clients through direct outreach and pharmaceutical conferences.
20-F for FY2025, filed Apr 1, 2026Our CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients…View ↗
Since inception, our CDMO business has secured multiple customer engagements, including both research and GMP manufacturing projects, and…View ↗
For our CDMO business, we pursue targeted marketing activities, including online advertisements, direct outreach campaigns and…View ↗
Do Revenues Turn Into Profits?
No. It lost $8.3M in FY2025.
20-F for FY2025, filed Apr 1, 2026
−$7.5MView ↗
20-F for FY2025, filed Apr 1, 2026
−$8.3MView ↗
20-F for FY2025, filed Apr 1, 2026
−$6.1MView ↗
How Are They Changing?
External CDMO services
The earlier report described the Jerusalem facility as supporting the company’s own NanoAb development and production; the latest report describes CDMO services for biotechnology clients, including process development and clinical manufacturing.
10-K for FY2022, filed Apr 17, 2023 20-F for FY2025, filed Apr 1, 2026
Therapy focus
The earlier report foregrounded a COVID NanoAb alongside a planned broader pipeline; the latest report says that program is suspended and describes candidates for inflammatory and immune conditions, including interleukin-targeting programs.
10-K for FY2022, filed Apr 17, 2023 20-F for FY2025, filed Apr 1, 2026BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing…View ↗
As part of the abovementioned turnaround, on December 22, 2021, the Company signed a definitive exclusive, worldwide, License Agreement…View ↗
On March 23, 2022, we signed a five-year Research Collaboration Agreement (“RCA”; collectively, with the LA and aRCA, the “MPG/UMG…View ↗
On June 5, 2023, as part of this collaboration, we entered into an exclusive worldwide license agreement to develop and commercialize…View ↗
We are currently advancing our IL-17 NanoAb program with two product profiles in development, subject to ongoing evaluation of development…View ↗
We have suspended active development of our COVID-19 NanoAb program due to changes in market conditions and are not currently pursuing…View ↗
Loading...
